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The role ofnitric oxide (NO) in neurological diseases represents one ofthe most studied,
yet controversial subjects in physiology. The aim was to examine the effects ofintrastriatal
injection neurotrophins (nervegrowth factors-NGF, fibroblast growth factors-FGF) in or-
der to investigate the possible involvement ofNO in quinolinic acid (QA) induced striatal
toxicity in the rat model ofHuntington's disease (HD). QA was administered unilaterally
into the striatum ofadult Wistar rats in a single dose of150 nM. The other two groups of
animals werepretreated immediately before QA application with NGF and FGF, respec-
tively. Control group was treated with 0.9% saline solution in the same manner. Animals
weredecapitated 7 days after the treatment. Nitrite levels weresignificantly decreased both
in the ipsi- and contralateral striatum and forebrain cortex of NGF- and FGF-treated
animals compared with QA treatment. These results indicated a temporal and spatial
propagation ofoxidative stressand spreadprotective effects ofNGF and FGFon the fore-
brain cortex, the distant structure, but tightly connected with striatum, the place ofdirect
neurotoxic damage. Neurotrophins could be thepotential neuroprotective agents in HD.
Key words: Huntington disease; disease models, animal; quinolinic
acid; nitric oxide; nerve growth factor; fibroblast growth
factor; oxidative stress.
Introduction
Huntington's disease (HD) is dominantly inherited,
untreatable neurological disorder featuring a progressive
loss of striatal output neurons that results in dyskinesia,
cognitive decline and ultimately, death (1). HD gene muta-
tion is an expanded and unstable trinucleotide repeat in a
new gene, which encodes a 349 kd protein. Huntingtin is a
widely expressed protein (e.g., in the testicles, heart, liver,
skeletal muscle, and lung), and its expression is high in the
brain, particularly in the hippocampus, cerebellar granular
cell layer, and Purkinje cells. Mutant huntingtin (and possi-
bly the polyglutamine tract itself) may induce the defective
mitochondrial function (2). The question then arises as to
the relevance of the mitochondrial defect to cell death in
the striatum. The striatum is known to be an area highly
dependent on oxidative phosphorilation for energy, and the
increased huntingtin binding in the striatum (e.g., via
huntingtin binding proteins such as huntingtin-associated
protein 1 [HAP-I]) may cause the impaired oxidative
phoshorilation, and in that way predispose neurons to the
cell death by its excitotoxicity. However, the cascade of
events in HD pathogenesis is likely to be much more com-
plicated and involve factors specific to the biochemistry and
pharmacology of the striatum (3, 4).
Besides the striatum, the forebrain cortex is also in-
cluded in the selectively vulnerable brain structures. Mas-
sive afferents from all areas of the cortex represent the
most important source of excitatory amino acids, whereas
the intrinsic circuits provide the striatum with acetylcholine,
GABA, nitric oxide and adenosine. All these neurotrans-
mitter systems interact with each other and with voltage-
dependent conductances to regulate the efficacy of the syn-
aptic transmission within this nucleus. The integrative ac-
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tion exerted by the striatal projection neurons on this con-
verging information dictated the final output of the stria-
tum to the other basal ganglia structures (5).
Ouinolinic acid (QA) is a selective agonist at receptors
for the glutamate analogue N-methyl-D-aspartate (NMDA)
and has become a widely used tool for the study of neu-
ronal damage resulting from the activation of these recep-
tors (6). Since it is an endogenous metabolite of trypto-
phan, it has also become a focus of interest for under-
stending of the pathological processes underlying neuronal
damage in HD (7). The mechanism by which QA produces
neuronal damage remains uncertain. The neurotoxicity of
QA is considerably greater than can be accounted for by the
activation of NMDA receptors. There are qualitative, as well
as pharmacological differences between the neurotoxic ef-
fects of NMDA and QA, which suggest the involvement of
mechanisms other than NMDA receptor activation (8).
One such mechanism may involve free radicals. Acti-
vation of glutamate receptors is known to induce an influx
of calcium ions into neurones, which starts a destructive se-
quence of events within the cell, possibly leading to the
generation of reactive oxigen species (9). Recent work has
shown that QA may lead to the generation of free radicals,
such as the release of nitric oxide (NO) in the brain (10).
The role of NO in this circumstances was controversial be-
cause the physiological chemistry of NO was complex and
encompassed numerous potentional reactions. It is con-
venient to separate NO chemistry into the direct and indi-
rect effects (11). Direct effects are those reactions in which
NO interacts directly with a bilogical molecule, whereas the
indirect effects are those reactions mediated by NO-derived
intermediates such as reactive nitrogen oxide species de-
rived from the reaction of NO with O2or superoxide (02}
Direct effects such as interaction of NO with metal-
containing proteins or with organic free radicals may occur
at the lower concentrations or fluxes of NO, whereas higher
NO fluxes can result in the indirect effects such as nitrosa-
tion, nitration and oxidation.
The delivery of neurotrophins (NTF) or their genes to
the CNS has shown a promise as a rational therapy for the
treatment of brain injury and neurodegenerative disorders
(12). A remarkably large number of proteins that mediate
development and responses to the injury were found to
protect neurons from excitotoxicity and to stimulate CNS
repair. These include nerve growth factor (NGF), fibroblast
growth factor (FGF), brain derived neurotrophic factor
(BDNF), neurotrophin (NT-3), neurotrophin 4/5 (NT-4/5)
and ciliary neurotrophic factor (CNTF) (13). In this paper it
was assumed that NGF and FGF could have the protective
effect on the propagation of oxidative stress caused by QA in
the rat model of Huntington's disease mediated by NO.
Methods
The investigation was performed on adult Wistar rats
of both sexes, with body mass about 250 g. Animals were
classified into four groups and were put in macrolen cages
(Erath, FRG). Animals had free access to food and water.
Average microclimate conditions were the following: room
temperature 23±2° C, air humidity 55±1O%; air was condi-
tioned by 10-50 exchanges per hour, and light regime was
in 12 hours cycles from 7 to 19 hours.
QA was administered unilaterally into the striatum in
the single dose of 250.7 Ilg (150 nM) using stereotaxic in-
strument for small animals and coordinate for the striatum
(8.4; 2.4; 5.0 mm). The second and the third group were
treated with QA and NGF (NGF in the dose of 7 ng), and
QA and FGF (FGF in the dose of 4 ng), respectively. Neu-
rotrophic factors were applied immediately after the neu-
rotoxin. Control group was treated with 0.9% saline solu-
tion in the same manner. For all treated animals injected
intracerebral volumens were 10 Ill.
Before the treatment animals were anesthetized by
pentobarbital sodium i.p. in a dose of 40.5 mg/kg b.m.
Animals were sacrificed by decapitation 7 days after
the treatment.
Prepared crude mitochondrial fraction of the striatum
and forebrain cortex was used for the appropriate bio-
chemical analysis (14).
NO is an important intra- and intercellular mediator
but its half-life in vivo is only a few seconds. Most of the
NO is oxidized to nitrite/nitrate, and the concentrations of
these anions were used as the quantitative indices of NO
production. The simplest and most widely used technique is
spectrophotometric measurement of nitrite using the Griess
reagent, which consisted of naphthylethylenediamine dihy-
drochloride in water and sulwocanilamide in phosphoric
acid. Griess reagent formed a purple azo dye with nitrite,
which could be measured with a spectrophotometer (15).
Mean values and SD were calculated for each pa-
rameter of interest. Differences between groups were ex-
amined using Student's independent r-test. The results were
considered to be significant at p<0.05.
Results
There was no significant difference in nitrite concen-
trations between ipsi- and contralateral side striatum and
cortex of control animals (Fig. 1, 2).
Nitrite level was evidently increased in the ipsi- and
contralateral striatum and forebrain cortex of QA treated
animals compared to controls (p<O.OOOl). The difference
of nitrite concentration in the striatum between ipsilateral
and contralateral side of QA treated animals was highly
significant (p<O.OOOl) but in the forebrain cortex there was
no difference.
In both groups of animals treated with neurotrophins
there was no significant change in the nitrite level com-
pared to the controls (Fig. 1, 2).
Nitrite levels were significantly decreased in the ipsi-
and contralateral striatum and forebrain cortex of neuro-
trophins treated animals. The differences of nitrite con-Iipoj 2 BOJHOCAHI1TETCKHm-arJIEn
Discussion
centration of NGF-treated and FGF-treated animals com-
pared to QA-treated animals were significant (ipsilateral
p<0.002 vs. NGF and FGF) and contralateral (p<0.02 vs.
NGF, p<O.0003 FGF).
death provided firm evidence that NO modulated the
NMDA channel in a manner consistent with both physio-
logical and pathophysiological role (17).
Under the pathological conditions, NO acts as a cal-
cium dependent neuromodulator and retrograde messen-
ger following stimulation of the NMDA receptor com-
plex. Our results indicated that the nitrite levels were in-
creased in the ipsi- and contralateral striatum of QA-
treated animals (Fig. 1). It was speculated that NO inter-
acted with superoxide anions resulting ultimately in the
production of neurotoxic hydroxyl radicals and nitrogen
dioxide (18). The neurodestructive effect of NO was
shown to occur due to various chemical stages such as ni-
trosonium ion, peroxynitrite, etc.
NO was implicated as a mediator of cell injury in HD.
Thus, NO as a free radical, might be involved in QA-
induced neurotoxicity and oxidative stress. Nitrite levels
were increased in the ipsi- and contralateral forebrain cor-
tex of QA-treated animals (Fig. 2). These results indicated
a temporal and spatial propagation of oxidative stress in the
forebrain cortex, the structure distant, but tightly connected
with striatum, the place of direct neurotoxic damage. Af-
fection of the contralateral forebrain cortex, as well as con-
tralateral striatum might be due to the cascade reactions of
reactive oxygen species and activated mechanism of exci-
totoxicity, as a sequel of defect in energy metabolism (19).
An inability to maintain cellular ATP levels might lead to
partial neuronal depolarization, relief of the voltage de-
pendent Mg2+ block of NMDA receptors, and persistent
activation of ambient glutamate levels (20). Glutamate-
induced calcium accumulation, as a result of slow excito-
toxicity, corelated with subsequent neuronal degeneration.
Neurotrophins were proposed as the candidates for
the treatment of neurodegenerative disease. NGF and FGF
differentially protect striatal and cortical projection neu-
rons and interneurons against the injection of the NMDA
receptor agonist, QA. Nitrite levels were evidently de-
creased in both ipsi- and contralateral striatum and fore-
brain cortex of NTF-treated animals (Fig. 1, 2). Therefore,
it was proposed that neurotrophins might have an impor-
tant role in the protection against neuronal damage fol-
lowing brain insults. Changes in trk expression levels could
be responsible for the differences in the vulnerability of
striatal neuronal populations observed after QA applica-
tion.
The main protective influence of NGF included its di-
rect and indirect participation in NO metabolism and its
effects to cellular homeostasis. NGF could have the pro-
tective effect on the propagation of oxidative stress caused
by QA (21).
A report that FGF can protect against glutamate neu-
rotoxicity, and that the FGF receptor (FGFR3), with its
gene located in the HD region on chromosome 4, appeared
in striatal neurons, made it tempting to speculate on a pos-
sibly important role for FGF-FGFR3 interactions in HD
pathology (22).
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Fig. 1 - Nitrite levels in the ipsi- and contralateral striatum
of QA- and NTF-treated Wistar rats. (Si, Sc=striatum ipsi-,
contralateral). Values are given as .umol nitrite/mg proteine
Mean ±SD *- Significance to corresponding values of QA-
treated group. p<0.05).
Nitric oxide (NO) is widely described as a neuronal
messenger showing both neuroprotective and neurotoxic
effects. It is also clear that NO is involved in many physio-
logical processes such as learning and memory, long-term
potentiation and apoptosis, among other functions. Under
pathological conditions, NO may promote oxidative stress
and cell damage (16). NMDA receptor activation increases
NO synthesis probably by increasing intracellular calcium
which binds to calmodulin, allowing it to activate nitric ox-
ide synthase - NOS. Striatal application of QA is associated
to neural damage through NMDA receptor activation and
increased NOS activity. NMDA receptor-mediated cell
Fig. 2 - Nitrite levels in the ipsi- and contralateral fore-
brain cortex of QA- and NTF-treated Wistar rats. (Cxi,
Cxc=forebrain cortex ipsi-, contralateral). Values are given
as .umol nitrite/mg proteine Mean ± SD ", Significance to
corresponding values of QA-treated group. (p<0.05).
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The present results indicated that striatal lesions in-
duced changes in the functional activity of basal ganglia nu-
clei and that the NTF partly reversed the alterations in the
functional state of the basal ganglia circuitry (23). It could
be proposed that the lesion-induced morphological changes
in the striatum and atrophic changes due to transsynaptic
degeneration, would be also less extensive in the NGF- and
FGF-treated animals.
NO is clearly a unique biological effector molecule but
has very complex physiological chemistry. Under the condi-
tions of normal release, NO is a neuronal messenger mole-
cule. With excessive release such as in the rat model of
Huntington's disease, NO may function as a cytotoxic mole-
cule mediating QA-induced cell death as well as being in-
volved in neurotoxicity and oxidative stress.
Conclusion
The results that were obtained at the 7
th day after the
intrastriatal unilateral application of NTF (NGF, FGF),
given before QA, were contrary to those induced by QA
only, such as:
decrease of nitrite level in ipsi- and contralateral
striatum,
decrease of nitrite level in ipsi- and contralateral
forebrain cortex.
Considering that NGF and FGF mediate their activity
accross glutamergic synapse/nitric oxide, and beside others
have also antioxidative effects, the obtained results indicate on
their protective role towards functional defects caused by QA.
In our study the in vivo cytoprotective effects of NTF against
striatal excitotoxic lesions suggest that these molecules could
be used as potential neuroprotective agents in HD.
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YTLtll...lAJ HEPBHOr Ltl etJLtl6P06nACTHOr etJAKTOPA PACTAHA npOLtl3BO,D,f-bY
A30T OKCLtlAA Y EKCnEPLtlMEHTHOM MO,I:\EnyXAHTLtlHrTOHOBE
60nECTLtl
Ynora a30T okeana (NO) y HeypoAereHepaTVlBHVlM 060Jbef-bViMa je VI nopezi VlH-
TeH3V1BHor Vl3Yl..laBaf-ba jow ysex KOHTpoBep3Ha. l...lVlJb paaa 6V10 je Aa ce VlcnVl-
Tajy eepeKTVI VlHTpacTpVljaTHe npVlMeHe HeypoTpoepVlHa Ha MOAeny XYHTVlHrTOH-
OBe 60neCTVI (X6) KOA nauosa KOjy Vl3a3V1Ba XVlHonVlHCKa KVlcenVlHa (XK) y
cMVlcny carnenaea-sa ynore NO. XK je annnxoeaaa VlHTpacTpVljaTHo, yHVlnaTep-
anao y A03V1 OA 150 nM. ,I:\pyre ABe rpyne >KVlBOTVlf-ba cy uenocpenuo npe Hey-
POTOKCVlHa A06V1ne HepBHVI cpaxrop pacra (HetJP), OAHOCHO epVl6p06naCTHVI
cpaxrop pacra (etJetJP). KOHTponHa rpyna rpernpaaa je 0,9% epVl3V1onowKVlM
paCTBOpOM Ha VlCTVI Ha'-lVlH. >KVlBOTVlf-be cy >KpTBOBaHe AeKanViTal.lVljoM 7 naua
HaKOH rperaaaa. KOHl.IeHTpal.lVlja HVlTpVlTa je CHVI>KeHa y VlncVI- VI xoarpanarep-
anHOM cTpVljaTyMy VI koprexcy >KVlBOTVlf-ba rperupaaax HeypoTpoepVlHVlMa. OBVI
peayrrrarn 6V1 MornVl Aa ynyre HaBpeMeHcKy VI npocropsy nponarauajy oxcazia-
TVlBHor crpeca VI npoumpesor nporexrneuor eepeKTa HetJP VI etJetJP Ha KOpy
npezuser M03ra, crpyxrypy xoja je onaojeaa, ana ooraro noaesaaa ca CTpVl-
jaTyMoM, MeCTOM AVipeKTHor HeypoToKcVI'-IHor ourreheisa. Heyporpocpaan Mory
6V1TVI nOTeHl.IVljanHVI HeyponpoTeKTVlBHVI areHCVI y X6.
K Ij ucnereci: Hantingtonova bolest; bolest, modeli na zivotinjama;
hinolinska kiselina; azot, oksid; faktor rasta, nervni;
faktor rasta, fibroblastni; stres, oksidativni.